Actualités

Aristotle Capital Management, LLC, an investment management company, released its “Core Equity Fund” first-quarter 2026 investor letter. A copy of the letter can be downloaded here. During the first quarter, the U.S. equity market declined, with the S&P 500 Index falling by 4.33%. The fixed-income sector also saw a downturn; the Bloomberg U.S. Aggregate Bond Index […]

Earlier in May 2026, Boston Scientific filed a US$565.7 million shelf registration for up to 10,000,000 common shares tied to an ESOP-related offering, while shareholders also approved charter amendments eliminating supermajority voting and adding limited officer exculpation under Delaware law. Taken together with recent director equity and deferred stock awards, these developments highlight a stronger emphasis on ownership-based incentives and refreshed corporate governance at the...

Morningstar now rates Boston Scientific (BSX) as significantly undervalued after a meaningful share price decline. The firm is flagging the stock as a potential opportunity for investors who focus on gaps between price and estimated fair value. See our latest analysis for Boston Scientific. Recent governance updates, including the removal of supermajority voting provisions and fresh director equity awards, have coincided with a sharp reset in sentiment, with the 30 day share price return down...

Boston Scientific rides on cardiovascular device growth with FARAPULSE and WATCHMAN momentum, but margin pressure and weaker estimates cloud the outlook.

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended holding Boston Scientific Corporation. “I don't understand how this thing could have fallen so fast,” he said of the medical device maker. “I know there's a lot of competition. I don't...

The latest generation of the coronary intravascular lithotripsy device is designed to be more flexible to help physicians navigate tight arteries to break up calcified deposits and restore blood flow.

Boston Scientific Corporation ( NYSE:BSX ) shareholders might have a reason to worry after multiple insiders sold their...

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.

Boston Scientific's Neuromodulation unit posts 15% organic sales growth in Q1, fueled by pain management gains, the acquisition of Nalu and momentum in Intracept.

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

SNN vs. BSX: Which Stock Is the Better Value Option?

Multiple securities class action lawsuits have been filed against Boston Scientific (NYSE:BSX), alleging misleading statements about the sustainability of U.S. electrophysiology growth. The cases focus on disclosures related to a key business segment and whether investors were given an accurate view of growth prospects. Several court ordered and attorney set deadlines are approaching for shareholders who may wish to participate in these actions. Boston Scientific is a large medical device...

We just covered Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and Boston Scientific Corporation (NYSE:BSX) ranks 9th on this list. Boston Scientific Corporation (NYSE:BSX) has consistently featured in the 13F portfolio of Farallon Capital since the third quarter of 2020. Back then, this position comprised just under 8.3 million shares. The fund steadily […]

Boston Scientific (NYSE:BSX) used its 2026 Annual Meeting of Stockholders to highlight 2025 operating performance and review a slate of governance and compensation proposals, including competing measures related to shareholders’ ability to call special meetings. Management highlights 2025 results a

Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Boston Scientific Corporation (NYSE:BSX) is one of the best medical device stocks to invest in right now. Argus cut the price target on Boston Scientific Corporation (NYSE:BSX) to $95 from $115 on April 27, reaffirming a Buy rating on the shares. The rating update came after the company’s fiscal Q1 earnings and guidance cut, with […]

Recently, Zacks.com users have been paying close attention to Boston Scientific (BSX). This makes it worthwhile to examine what the stock has in store.

Boston Scientific has lagged behind the broader market over the past year, yet analysts remain highly bullish about the stock’s prospects.

Boston Scientific Corporation (NYSE:BSX) was among the stocks Jim Cramer covered on Mad Money as he discussed the wave of IPOs being the market’s possible biggest threat. Answering a caller’s query about the stock, Cramer commented: Well, the competition just got too strong for Boston Scientific. They’re always one step out of the posse, and […]